{'fraction_non_alphanumeric': 0.03214285714285714, 'fraction_numerical': 0.041666666666666664, 'mean_word_length': 4.964539007092198, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Beta-2 Receptor Agonist Exposure in the Uterus Associated With Subsequent Risk of Childhood Asthma

K Ogawa, S Tanaka, Y Limin. Pediatr Allergy Immunol. 2017;28(8):746–753

Several studies have revealed that the continuous use of long-acting β2-agonist is a potential risk for patients with asthma, but none have revealed the potential effect of in utero exposure on the subsequent risk of childhood wheeze and asthma. The authors of this study examined the association between intrauterine exposure to β-2 receptor agonist (B2RA) and asthma in offspring.

Data were obtained from a hospital-based cohort study in Tokyo, Japan, from 2003 to 2005. Researchers initially interviewed 1701 pregnant women, and 1550 infants were enrolled and followed up with during childhood and adolescence.

Mothers were enrolled before 16 weeks’ gestation. …